Current Pharmaceutical Design

William A. Banks  
VAPSHCS/GRECC S-182
Building 1, Room 810A
1600 S. Columbian Way
Seattle, WA 98108
USA

Back

Non-Alcoholic Fatty Liver Disease in the Metabolic Syndrome

Author(s): Giuseppe Palasciano, Antonio Moschetta, Vincenzo O. Palmieri, Ignazio Grattagliano, Gianluca Iacobellis and Piero Portincasa

Affiliation: Clinica Medica “A. Murri”,Department of Internal&Public Medicine, University of Bari, Policlinico,P.zza G. Cesare 11, 70124 Bari, Italy

Abstract:

Non-alcoholic fatty liver disease (NAFLD) is often associated with features of the metabolic syndrome, carrying an increased risk to develop non-alcoholic steatohepatitis (NASH), the inflammatory form of liver steatosis. Epidemiological data confirm that obesity, diabetes, hypertension and hyperlipidemia are frequently found in NAFLD and worsen its prognosis because of increased risk of fibrotic evolution, eventually leading to liver cirrhosis. Recent studies confirm the close relationship between the metabolic syndrome and liver steatosis, and further support the detrimental role of oxidative stress and lipid peroxidation, which are pathophysiological processes present in both conditions. Novel diagnostic tools and life style modifications together with targeted therapeutic actions are urgently needed for the management of liver dysfunction in course of metabolic syndrome.

Keywords: Metabolic syndrome, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, breath test

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

VOLUME: 13
ISSUE: 21
Page: [2193 - 2198]
Pages: 6
DOI: 10.2174/138161207781039652